How to Get Ahead in BD Deals? Decoding Biotech's Proactive BD Strategy

Add the assistant's QR code to register for the event:

MediLink, founded in 2020, is a clinical-stage biopharmaceutical company focused on the development of innovative conjugate drugs. It has developed its latest generation of Tumor Microenvironment Activable LINker-payload (TMALIN) technology with independent intellectual property rights.^®) Novel antibody-drug conjugate (ADC) platform technology enables homogeneous and stable conjugation with high drug-to-antibody ratio (DAR), while further widening the therapeutic window of ADC drugs and enhancing their efficacy in solid tumors, with the aim of providing better treatment options for cancer patients worldwide. The company is headquartered in Suzhou, China, and has established R&D branches in Shanghai, China, and Boston, USA.

Legend Capital, established in April 2001, is a fund management company under Legend Holdings Corporation, specializing in early-stage venture capital and growth-stage private equity investments. Over the past two decades, Legend Capital has adhered to international standards, creating best practices in fund operations and management. Through its proactive value-added service system, Legend Capital fosters innovative corporate growth, delivering consistent strong investment returns across multiple sectors while driving industrial advancement and social development in China. With the vision of “becoming an internationally influential investment firm,” Legend Capital upholds the core value of “Wealth with Integrity” and actively fulfills its social responsibilities.

YAFO Capital, established in 2013 as a novel investment and investment banking advisory firm, is dedicated to investing in, providing financing services for, introducing products, and incubating assets for biopharmaceutical projects in China and overseas. Its affiliated YAFO Fund collaborates with pharmaceutical companies on asset investment and mergers and acquisitions, while YAFO Global Healthcare focuses on cross-border and domestic licensing transactions of pharmaceutical products. Leveraging YAFO’s extensive global network of connections and resources, the firm has successfully facilitated the entry of numerous overseas projects into the Chinese market and assisted multiple Chinese products in securing overseas licenses over the past decade. YAFO boasts an experienced global transaction team covering major pharmaceutical innovation hubs worldwide, including the United States, Japan, and Europe. Its core partners are seasoned Wall Street investment bankers or professionals with experience in multinational pharmaceutical companies, providing robust support for client transactions. Headquartered in Shanghai, YAFO maintains branch offices in London, Los Angeles, Tokyo, Milan, and Cambridge. YAFO has ranked first in the number of cross-border licensing and M&A transactions in the biopharmaceutical sector for three consecutive years.

Adock, initiated by the Mint Angel Fund, is committed to becoming China’s first innovation incubation center at the intersection of information technology (IT) and biotechnology (BT). By introducing and incubating life and health startups powered by IT support, Adock builds a cross-disciplinary innovation ecosystem, bolstered by professional infrastructure platforms and robust scientific incubation services.

VB New Medicine is a media and research platform under VCBeat that focuses on the biopharmaceutical sector. It provides entrepreneurs and innovators with “in-depth” and “incremental” communication value through both content and operational dimensions. In terms of content, it primarily features exclusive financing announcements, corporate interviews, in-depth industry analyses, and sector reports. Operationally, through its branded column “VB Think Tank,” it focuses on practical challenges, discusses industrial trends, and fosters tangible collaborations through the exchange of ideas.

Special Report Findings:【CGT】[RNA Therapeutics]【iPSC】[Radiopharmaceuticals]【CXO】[Upstream Tools][Synthetic Biology][Organoids and Organ-on-a-Chip][IPO Financial Report Analysis]Wait

VB Thinkers’ Club is one of VCBeat’s flagship events, serving as a face-to-face platform centered on exploring solutions in the pharmaceutical and healthcare sectors, with the mission to “focus on practical challenges and discuss industry trends.” The event conducts in-depth discussions, analyses, and idea exchanges around the current development status of core themes, addressing encountered difficulties, pain points, and barriers. Meanwhile, it delves into the resource endowments of enterprises, fostering practical collaborations through intellectual exchange. “Each edition features one theme, one vehicle, and one ecosystem.”